Aroa Biosurgery (ASX:ARX) prints NZ$12.6m EBITDA then guides it lower for FY27

A deliberate NZ$9m reinvestment behind Myriad and Symphony is the real story buried under the FY27 guide-down

Aroa Biosurgery (ASX:ARX) just delivered the cleanest annual result it has ever printed (at least since it listed), then guided FY27 EBITDA materially lower. Both moves are deliberate, and both deserve unpacking.

The company’s revenue came in at NZ$103.9 million. This was up 23% on FY25 and beat the top of guidance on a constant currency basis. Normalised EBITDA tripled to NZ$12.6 million against guidance of NZ$5 to NZ$8 million. The company is now self-funding with NZ$27.1 million in cash and no debt.

Myriad did the heavy lifting. Revenue grew 54% to NZ$49.5 million and now sits ahead of the OviTex portfolio for the first time. Management noted this was achieved with the same sales headcount as FY25, which is the cleanest evidence yet that operating leverage is real.

Then comes the FY27 guide. Revenue of NZ$115 to NZ$125 million implies 13 to 23% growth, but EBITDA of NZ$8 to NZ$11 million is a step DOWN from FY26. The reason is a deliberate NZ$9 million reinvestment in sales headcount and Symphony infrastructure.

Why Myriad at 54% growth changes the valuation conversation

Myriad is now the largest single product line in the Aroa portfolio. At NZ$49.5 million it has overtaken the OviTex franchise sold through TELA Bio, which grew just 8% to NZ$42.8 million. That mix shift matters because Myriad is sold through Aroa’s own direct sales force, where the company keeps the full margin.

Direct channel revenue is now 59% of total product sales, up from 53% a year ago. Gross margin held at 85.5%, which tells us the channel mix change is sticking without eroding pricing.

The kicker is productivity. Achieving 54% growth without adding sales heads is not something a struggling commercial team can do. It signals that existing reps are landing larger accounts and selling deeper into them.

The NZ$9m reinvestment is a tell, not a setback

On the surface, guiding EBITDA down from NZ$12.6 million to NZ$8 to NZ$11 million while revenue grows looks like a step backwards. We think it is the opposite. Management is choosing to plough the FY26 outperformance back into the commercial machine rather than let it drop to the bottom line.

The investment splits across two pillars. More Myriad sales capacity to compound the productivity story, and a push behind Symphony, a new skin substitute product targeting a market management describes as undergoing a reimbursement reset.

Our concern is that Symphony is essentially unproven commercially, and the skin substitute market is competitive. The NZ$9 million is being committed before the product has demonstrated traction.

TELA Bio is now the slowest-growing piece of the story

OviTex revenue through TELA Bio grew just 8%, and FY27 guidance assumes TELA Bio sales are flat. That is a notable shift from the days when the partnership did most of the commercial heavy lifting.

Worth noting, the growth rate assumption used inside the TELA Bio accrual was cut sharply this year. OviTex revenue growth was revised to 2.7% from 19%, and OviTex PRS to 15.8% from 37%. That reset tells you management is taking a more conservative view of the TELA Bio runway.

The strategic implication is that Aroa’s growth story is now genuinely a direct sales story. The partnership is the cash cow, not the growth engine.

The Investors Takeaway for Aroa Biosurgery

The FY27 guide forces investors to take a view on management’s reinvestment discipline. The Myriad track record argues that ploughing capital into the commercial engine works. The Symphony bet is less proven and depends on a reimbursement environment that has only just started to reset.

We think the next two quarterlies are the real test. If Myriad direct sales productivity holds while headcount expands, FY28 starts to look very different to FY27. Investors can review our take on the FY26 preliminary print at stocksdownunder.